#United States #Miami #Chronic Pain #Consano Bio #C-1101

Consano Bio to Present at BIO Investment & Growth Summit 2026

Consano Bio, a pioneering biotechnology firm focused on developing advanced treatments for severe pain conditions, has made headlines with the announcement of its participation at the BIO Investment & Growth Summit scheduled for March 2–3, 2026, in Miami, Florida. The company’s CEO, Andrew Hall, will be at the forefront, elucidating their forward-thinking development strategies and the promising clinical journey of their lead investigational therapy, C-1101.

The Highlight: C-1101 Therapy

C-1101 represents an innovative approach in the realm of pain management, specifically targeting chronic lumbosacral radiculopathy, commonly known as chronic sciatica. This condition is particularly challenging, as it afflicts numerous individuals yet lacks any FDA-approved pharmaceutical remedies. Hall's presentation aims to shed light on how C-1101 works as a novel treatment option, filling a crucial gap in medical care for patients experiencing this distressing condition.

Chronic lumbosacral radiculopathy arises from damage or irritation to the roots of spinal nerves, leading to debilitating symptoms like pain, numbness, and weakness that can extend down the leg. The absence of effective treatments compounds the challenges faced by these patients, contributing to significant personal and societal costs.

About C-1101

C-1101 stands out as a groundbreaking candidate – a platelet-derived multi-protein biologic therapeutic. It's not just a treatment; it’s a new class of medicine designed to address the root cause of chronic sciatica by modulating inflammation and encouraging cellular repair in the affected regions. This product is unique, utilizing a purified, multi-protein formulation derived from human platelets sourced from healthy donors. By delivering a potent blend of cytokines, growth factors, and matrix proteins directly to the site of nerve injury through an epidural injection, C-1101 aims to invoke the body’s natural healing response efficiently.

During the summit, Hall's insightful overview will be complemented by one-on-one discussions between Consano Bio's management team and potential investors and partners. This direct engagement is crucial in forming strategic alliances that could accelerate the company's vision and broaden the therapeutic landscape for chronic pain management.

About Consano Bio

Founded in 2023 and headquartered in the Greater Boston area, Consano Bio is dedicated to revolutionizing treatment methodologies for debilitating orthopedic conditions. The firm has built its reputation on novel multi-protein therapeutics like C-1101, designed explicitly to provide relief from chronic pain that significantly impacts patients’ quality of life. The company’s commitment to addressing unmet medical needs positions it as a significant player in biotechnology, particularly in pain treatment innovation.

With hopes of aligning strategic interests, Consano Bio also aims to capture the attention of investors during the summit, potentially unlocking further development of their cutting-edge therapies. As they prepare for this pivotal event, the biotechnology sector eagerly anticipates the insights and innovations shared by Consano Bio.

For more detailed insights into Consano Bio and its mission to transform how chronic pain is treated, visit www.consanobio.com.